EODData

MEMBERSHIP REGISTER LOG IN

FRA, I54: BIOCYTOGEN PHARMA. H YC1

02 Oct 2025
LAST:

3.130

CHANGE:
 0.01		OPEN:
3.160		HIGH:
3.160		ASK:
0.000		VOLUME:
967
CHG(%):
0.32		PREV:
3.140		LOW:
3.120		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 253.1603.1603.1203.130967
01 Oct 252.9553.1402.9503.1400
30 Sep 253.1053.1053.0853.1001.3K
29 Sep 253.1453.1453.0903.0901.3K
26 Sep 253.1703.1703.1153.1151.3K
25 Sep 253.1953.2053.1903.1901.3K
24 Sep 253.0203.0453.0203.0451.3K
23 Sep 252.9402.9702.9152.9151.3K
22 Sep 252.9903.0102.9902.9902K
19 Sep 252.9252.9402.9252.9302K

COMPANY PROFILE

Name:BIOCYTOGEN PHARMA. H YC1
About:Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs in the People's Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4-tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors. In addition, its preclinical candidates include YH012 and YH013, fully human anti-HER2/TROP2 bispecific antibody drugs conjugate for therapeutic product development, manufacturing, and commercialization for all human indications; YH015, a fully human IgG1 antagonistic monoclonal antibody targeting CD40; and YH016 and YH017, two novel molecules. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
Sector:Healthcare
Industry:Biotechnology
Address:12 Baoshen South Street, Beijing, China
Website:https://www.biocytogen.com
ISIN:CNE100005D27

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:68.50
Price to Book:9.63
Price to Sales:0.97
EBITDA:382.48M
Shares:108.27M
Market Cap:338.89M

TECHNICAL INDICATORS

MA5:3.12
MA10:3.06
MA20:2.90
MA50:2.71
MA100:2.39
MA200:1.78
STO9:74.14
STO14:89.66
RSI14:63.74
WPR14:-8.45
MTM14:0.45
ROC14:0.17
ATR:0.12
Week High:3.21
Week Low:2.95
Month High:3.21
Month Low:2.48
Year High:3.21
Year Low:0.61
Volatility:91.88